<h3>Key Takeaways:&nbsp;</h3>
<ul>
<li>Life sciences M&amp;A is rebounding to a more favorable environment in 2026, with higher-value, strategic deals offsetting lower overall deal volume.</li>
<li>The&nbsp;<a href="https://www.drugpatentwatch.com/blog/beyond-the-drug-patent-cliff-how-procurement-can-drive-immediate-savings-with-generics-and-biosimilars/">patent cliff</a> is acting as a catalyst for big pharma to focus on acquiring growth-focused assets and late-stage pipelines, rather than relying on long-risk R&amp;D.</li>
<li><a href="https://www.pwc.com/us/en/industries/health-industries/library/medtech-deals-outlook.html">AI, digital transformation, and consumer-centric care</a> are reshaping deals, with many transactions targeting AI-enabled platforms and data-driven innovation.</li>
<li>Resourcing and workforce planning are becoming more critical as talent scarcity and M&amp;A-driven attrition/displacement puts pressure on companies to fill roles.</li>
</ul>
<hr>
<p>The life sciences industry is no stranger to peaks and troughs in mergers and acquisitions (M&amp;A) trends, particularly in the post-pandemic era. However, after a <a href="https://www.reuters.com/markets/deals/dealmakers-see-rebound-after-global-ma-volumes-hit-decade-low-2023-12-21/">dip in 2023</a>, factors seem to be influencing a more optimistic, favorable M&amp;A environment.</p>
<p>As we continue to move through 2026, industry stakeholders need to understand the factors influencing these deals and the way they impact the supply of highly-skilled talent in the life sciences sector.</p>
<h2>The Current Life Sciences M&amp;A Outlook</h2>
<p>Despite volatility due to evolving global trade policies and higher interest rates, the total deal value in the life sciences industry reached <a href="https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-dealmaking-gains-momentum-as-strategic-pressures-intensify">$372bn in 2025</a> (an increase of 47% year-over-year), with the Americas accounting for <a href="https://www.pwc.com/gx/en/services/deals/trends/health-industries.html">73% of the total</a> and dominating in terms of deal value.</p>
<p>Though overall deal volume is lower, there has been a shift instead to higher-impact, strategic transactions instead, driven by life sciences companies seeking to overcome the drawn-out timelines and high-risk nature of R&amp;D.</p>
<p>Between biotechnology, pharmaceutical, and medtech companies, the contribution to M&amp;A&rsquo;s uptick has been relatively equal (about 30% of deal volume). Biopharmaceuticals in particular have been characterized by growth-focused M&amp;A &mdash; between 2020 and 2025, <a href="https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-dealmaking-gains-momentum-as-strategic-pressures-intensify">76% of deals were focused on growth</a>, compared to 34% a decade ago. MedTech has entered into 2026 with a healthier M&amp;A environment due to <a href="https://pmcf.com/perspectives/2026-medtech-ma-outlook-strengthens-as-buyers-prioritize-innovation-and-resilience/">improved financing conditions and sector resilience</a>.</p>
<p>Pipeline pressures continue to influence life sciences M&amp;A trends, as businesses look to navigate evolving regulatory requirements causing a <a href="https://www.drugpatentwatch.com/blog/beyond-the-drug-patent-cliff-how-procurement-can-drive-immediate-savings-with-generics-and-biosimilars/">&ldquo;patent cliff&rdquo;</a> for large pharma, in which a revenue risk of $300bn in annual branded drug revenue is at risk of being lost to generic and biosimilar competition between 2025-2030.</p>
<h2>Key M&amp;A Life Sciences Deal Activity</h2>
<ul>
<li><strong>Johnson &amp; Johnson acquired Intra-Cellular Therapies, Inc </strong>in Q2 2025 for $14.6bn, with particular emphasis on CAPLYTA&reg;, a schizophrenia and bipolar disorder drug.</li>
<li><strong>Novartis acquired Avidity Biosciences </strong>in Q1 2026 for $12bn, aiming to strengthen Novartis&rsquo; late-stage neuroscience pipeline.</li>
<li><strong>Pfizer acquired obesity biotech Metsera </strong>for up to $10bn in November 2025, following a surprise bid from Novo Nordisk, with additions to their pipeline including MET-097i, a weekly and monthly injectable GLP-1 receptor agonist.</li>
<li><strong>Merck &amp; Co. acquisition of Verona Pharma</strong> announced in Q4 2025, valued at $10bn and boosting Merck&rsquo;s respiratory portfolio, centered on Ohtuvayre, a maintenance treatment for Chronic Obstructive Pulmonary Disease (COPD).</li>
<li><strong>Novo Nordisk acquired Akero Therapeutics </strong>in October 2025 for up to $5.2bn, and its metabolic dysfunction-associated steatohepatitis (MASH) candidate efruxifermin.</li>
</ul>
<p>These acquisitions represent the significant reshaping of big pharma portfolios, specifically in relation to the &ldquo;patent cliff&rdquo;, alongside the rebound of global deal activity towards larger-scale, high-impact deals &mdash; as with <a href="https://redbock.com/news/life-sciences-m-a-outlook/">2025 mergers and acquisitions of note</a>, addressing unmet medical needs is still a key focus of many transactions.</p>
<h2>The Trends Impacting Life Sciences M&amp;A</h2>
<h3>Patent cliffs in biologics pharma driving diversification</h3>
<p>The patent cliff wave has continued to impact life sciences mergers and acquisitions, with a cluster of widely prescribed small-molecule drugs set to lose protection in 2026 across primary care, cardiology, and immunology, pushing companies to favor lower-cost versions to reduce revenue risk.</p>
<p>A <a href="https://www.sec.gov/Archives/edgar/data/310158/000162828025017867/formars202410-k.pdf">2024 annual report by Merck</a> noted the pressure points facing Keytruda, a prescription immunotherapy medication. It expects U.S. sales to decline in January 2028 with government pricing under the Inflation Reduction Act, then further decline after a loss of exclusivity due to the expiration of the U.S. compound patent in 2028. This is just one example of how originators attempt to hold share when a biologic is on the approach to losing exclusivity.</p>
<h3>Consumer-centric, Tech-enabled care</h3>
<p>M&amp;A is one of the fastest ways to catalyze digital innovation, and the deals that stand out in the future will be those backed by <a href="https://www.pwc.com/gx/en/services/deals/trends/health-industries.html">AI-enhanced productivity</a>, differentiated data, evidence-backed innovation, and clear pathways to long-term value creation.</p>
<p>An example of the high-innovation shift in life sciences M&amp;A was one of medtech&rsquo;s largest ever AI deals in <a href="https://investor.gehealthcare.com/news-releases/news-release-details/ge-healthcare-acquire-intelerad-advancing-cloud-enabled">GE HealthCare&rsquo;s $2.3bn acquisition of Intelerad</a>, aimed at accelerating GE HealthCare&rsquo;s D3 strategy (disease-focused devices enabled by digital and AI).</p>
<h3>Therapeutic Focus That Sets Standards of Care</h3>
<p>Areas such as cardiometabolic, CNS, oncology, and immunology are still maintaining a strong pace of innovation which continues to drive financial and strategic interest for capital allocation. According to a <a href="https://kpmg.com/us/en/media/news/2026-hcls-investment-outlook.html">KPMG study</a>, oncology and immunology are anticipated to be the most competitive areas for acquisition by biopharma professionals.</p>
<p>In pharma in 2025, oncology was at the top of dealmaking with <a href="https://www.deloitte.com/us/en/industries/life-sciences-health-care/articles/mergers-and-acquisitions-trends-survey-life-sciences.html">30% of $120bn deals</a>, with buyers focusing on immune cell therapies, multi-specific antibodies, and radioligand technologies, while neurology, rare disease, and cardiovascular drove $36bn in transactions.</p>
<p>Technological innovation and digital transformation are also key areas across subsectors, with 90% of medical devices respondents expecting <a href="https://kpmg.com/us/en/media/news/2026-hcls-investment-outlook.html">10% or more of deals to incorporate artificial intelligence or machine learning</a>. <a href="https://www.pwc.com/us/en/industries/health-industries/library/medtech-deals-outlook.html">AI-driven analytics, robotics platforms, and connected-care ecosystems</a> are prioritized targets, acting as deal catalysts.</p>
<h3>Portfolio Optimization</h3>
<p>In 2025, a number of key markers have impacted deal activity and the shaping of portfolios, including:</p>
<ul>
<li>A shift toward acquisitions of single or smaller portfolios of clinical assets</li>
<li>An emphasis on acquiring mature, high-growth technologies in medtech</li>
<li>The absence of mega-deals, particularly in healthcare, driving a shift toward operational optimization and risk management</li>
</ul>
<p>In short, acquisitions are becoming more strategic and specific to address gaps, further innovation, and strengthen growth after a period of economic uncertainty.</p>
<h2>What to Expect in Life Sciences M&amp;A For the Rest of 2026</h2>
<p>The outlook for life sciences M&amp;A activity in 2026 is favorable &mdash; a combination of fast transformation and a surge of higher-value deals make 2026 a year of capitalizing on innovation. In a KPMG study, <a href="https://www.deloitte.com/us/en/industries/life-sciences-health-care/articles/mergers-and-acquisitions-trends-survey-life-sciences.html">67% of respondents expected more deals in 2026 than 2025</a>, with a higher percentage anticipating growth in deal volume rather than fewer transactions.</p>
<p>A few of the trends we expect to see include:</p>
<ul>
<li><strong>Urgency to restock pipelines: </strong>The patent cliff will drive pharma companies to double their efforts to develop or acquire the next generation of top-selling medications.</li>
<li><strong>Strong financial capacity for M&amp;A: </strong>Industry leaders should have considerable financial resources to make more strategic acquisitions, given that in 2025, <a href="https://kpmg.com/kpmg-us/content/dam/kpmg/pdf/gated/2026/hcls-investment-outlook-2026.pdf">23 companies had a combined cash and debt capacity of nearly $1.4 trillion</a>.</li>
<li><strong>Artificial intelligence: </strong>AI is an emerging catalyst for M&amp;A activity, as AI-powered platforms transform drug discovery, clinical trial management, and administrative operations, with many looking to fully integrate these capabilities.</li>
<li><strong>Regulatory changes: </strong>The broader life sciences regulatory environment is driving the portfolio shift towards high-value, strategic assets rather than relying on internal R&amp;D pipelines, and deal complexities and timelines are likely to be impacted by regulatory changes.</li>
</ul>
<h2>What This Means for Resourcing and Workforce Planning in Life Sciences</h2>
<p>An optimistic M&amp;A outlook in the life sciences industry goes hand-in-hand with a more competitive market for finding resourcing solutions and workforce planning. The demand created by the M&amp;A market is influencing a demand for specialized support to secure those with regulatory, tech-enabled, and commercial skillsets.</p>
<p>During M&amp;A changeovers, attrition and displacement can cause turbulence as employees consider their options and overall job security, increasing turnover rates and creating further strain on companies during an already challenging time.</p>
<p>Scarcity of talent is driving more strategic workforce planning, particularly as the life sciences industry continues to experience periods of highs and lows in growth of employment. Whilst <a href="https://www.cbre.com/insights/reports/us-life-sciences-talent-trends-2025">U.S. life sciences employment reached a record of 2.1 million in March 2025</a>, it fell measurably in April 2025, as <a href="https://4413123.fs1.hubspotusercontent-na1.net/hubfs/4413123/Insight%20Reports%20and%20Surveys/202601%20-%202026%20Employment%20Outlook%20Report/BioSpace%20-%202026%20Employment%20Outlook%20Report.pdf">high competition and layoffs</a> are still impacting the industry, making partnering with a consultancy firm highly advantageous for businesses looking to be more strategic and adaptable.</p>
<h2>Partner With Us: Your Leading Life Sciences Consulting Firm</h2>
<p>Redbock is a leading , providing FSP and contract resourcing solutions that help businesses through challenging M&amp;A transition periods. We align customized solutions to your business post-merger, ensuring that our solutions help you onboard and retain skilled professionals when you need them most to thrive in the ever-changing, competitive life sciences market.</p>
<p>If your organization is looking for highly skilled life sciences consultants to support your business during a period of change, <a href="https://redbock.com/contact/">contact us today</a> to navigate the transition and future changes with confidence.</p>
<hr>
<h2>Frequently Asked Questions: Life Sciences M&amp;A</h2>
<h3>What top trends are shaping life sciences M&amp;A activity in 2026?</h3>
<p>The top trends impacting life sciences M&amp;A activity in 2026 are: the patent cliffs, driving more strategic and high-quality deals to fill pipeline gaps; digital transformation, with an emphasis on deals backed by AI-enhanced productivity; therapeutic focus areas continuing to drive deals, including cardiometabolic, CNS, oncology, and immunology.</p>
<p>Regulatory and policy changes are also catalyzing portfolio restructuring, and deal activity is rooted in strategy rather than simply just buying assets to meet these new demands and developments.</p>
<h3>Which life sciences companies have been most involved in recent M&amp;A deals?</h3>
<ul>
<li><strong>Johnson &amp; Johnson:</strong> Acquired Intra-Cellular to strengthen its neuroscience portfolio.</li>
<li><strong>Merck:</strong> Bought Verona Pharma for respiratory growth, adding Ohtuvayre to its lineup.</li>
<li><strong>Pfizer:</strong> Acquired Metsera to build their portfolio in the obesity and cardiometabolic pipeline.</li>
<li><strong>Novartis:</strong> Agreed to acquire Avidity Biosciences to improve its RNA drug-delivery capability and strengthen its late-stage neuroscience pipeline.</li>
</ul>
<h3>What are the most common post-merger integration challenges in life sciences?</h3>
<p>Some of the biggest post-merger integration challenges in life sciences are operational disruption, cultural misalignment, failure to meet financial targets, IT integration difficulties, loss of key talent, and low morale, according to a <a href="https://www.travelers.com/resources/business-industries/life-sciences/life-sciences-mergers-acquisitions">Travelers report</a>.</p>
<h3>What should I look for when selecting a life sciences consulting partner?</h3>
<p>A good <a href="https://redbock.com/about-us/">life sciences consulting partner</a> should bring extensive industry experience, regulatory and compliance knowledge, and sector-specific awareness of the challenges in the current life sciences hiring market to the table. Supports should be tailored to your specific subsector and practical processes (e.g., integrating teams, or supporting day-one execution after a deal).</p>

Life Sciences M&A Trends in 2026

<h3>Summary:</h3>
<ul>
<li>AI in life sciences is accelerating and improving drug discovery, clinical trial efficiency, diagnostics, and enabling personalized medicine.</li>
<li>Generative AI, machine learning, deep learning, NLP, and agentic AI are transforming every stage of the life sciences value chain.</li>
<li>New research shows AI could reduce drug development timelines by 1&ndash;4 years and cut costs by 35&ndash;45%.</li>
<li>AI‑driven methods have already contributed to a large number of drug candidates and are impacting clinical trial design and patient resourcing.</li>
</ul>
<hr>
<h2>AI&rsquo;s Expanding Role in Life Sciences</h2>
<p>Artificial Intelligence has a huge role to play within life sciences, and has become one of the most influential technologies in the industry. With vast amounts of data generated daily through research, clinical trials, diagnostics, and real‑world evidence, AI provides the analytical power needed to interpret this information at scale, much more quickly than if humans were to do so.</p>
<p>AI makes use of various complex tools and networks to mimic human intelligence. The software and systems involved can learn from data, recognize patterns, and make predictions and independent decisions to reach a given goal.</p>
<p>Although AI first emerged in the 1970s, its application in life sciences has quickened dramatically in the last decade. The rise of machine learning (ML), deep learning (DL), natural language processing (NLP), and, more recently, generative AI (GenAI) and agentic AI has opened new possibilities across the entire industry.</p>
<h2>AI in Drug Discovery and Development: Millions of molecules and potential drugs to be discovered</h2>
<p>Drug discovery has traditionally been slow, expensive, and high‑risk. Even today, bringing a single new medicine to market can take more than a decade, can cost more than $2.6 billion, and around 90% of drug candidates fail during discovery and development (<a href="https://www.accenture.com/us-en/insights/life-sciences/reinventing-life-sciences-age-generative-ai">Accenture, 2024</a>). Part of the challenge comes from the sheer scale of chemical space, with the number of potential drug‑like molecules estimated at 10⁶⁰, far beyond what humans or traditional computational methods can screen.</p>
<p>Most approved medicines are still chemically synthesized small molecules, valued for their stability, simpler manufacturing, and ease of administration. But their lower specificity can increase the risk of side effects, which contributes to high failure rates in clinical trials.</p>
<p>Advances in biotechnology have expanded the therapeutic market to include larger, more complex biologics, which offer greater target specificity and have become a major growth area in pharma pipelines. But whether developing small molecules or biologics, the core challenge remains the same in identifying the right candidates quickly, accurately, and cost-effectively.</p>
<h3>How AI enhances drug discovery</h3>
<p>Modern models can sift through enormous libraries of compounds, predict how they might behave, and highlight the most promising options far faster than traditional methods. By 2024, more than <a href="https://www.torys.com/our-latest-thinking/publications/2025/12/ais-transformation-of-the-life-sciences-industry">70 investigational drug applications</a> involving AI or ML have been submitted to the US FDA, demonstrating how quickly the field is evolving. AI can:</p>
<ul>
<li>Predict 3D protein structures</li>
<li>Model drug‑target interactions</li>
<li>Forecast toxicity and side‑effects</li>
<li>Optimize molecular design</li>
<li>Generate entirely new drug candidates using GenAI</li>
</ul>
<p>Deep learning has improved the accuracy of protein‑structure prediction, and newer approaches, including <a href="https://www.mckinsey.com/industries/life-sciences/our-insights/reimagining-life-science-enterprises-with-agentic-ai">Agentic AI</a>, are beginning to automate multi‑step scientific tasks such as hypothesis generation and experiment planning.</p>
<h3>Impact on timelines and cost</h3>
<p>Accenture&rsquo;s analysis suggests that generative AI could shorten development timelines by one to four years and reduce the cost of a successful drug by 35&ndash;45%. For companies dealing with patent cliffs, pricing pressure, and slower growth, these gains are significant.</p>
<h2>AI in Clinical Trials</h2>
<p>Clinical trials are one of the most resource‑intensive and time-consuming stages of drug development. Delays in resourcing, protocol amendments, and inconsistent data often slow progress. AI is now helping to ease these bottlenecks.</p>
<h3>Improving trial design and resourcing</h3>
<p>Big data and AI complement each other, enabling researchers to analyze and synthesize vast datasets that were previously too complex to handle. AI and ML can now draw on historical trial data, real-world evidence, and patient records to:</p>
<ul>
<li>Determine appropriate sample sizes</li>
<li>Predict which patients are most likely to drop out</li>
<li>Select trial sites with higher enrolment potential</li>
<li>Match eligible patients to studies more quickly</li>
</ul>
<p>AI‑powered feasibility modelling and patient‑identification tools help to reduce resourcing timelines and improve trial diversity, two long-standing challenges in clinical research.</p>
<h3>Accelerating resourcing through intelligent automation</h3>
<p>Traditionally, resourcing has required large amounts of manual review, especially of unstructured text. Technologies such as natural language processing (NLP), machine learning, deep learning, and optical character recognition (OCR) can now:</p>
<ul>
<li>Sort through medical records to identify patients who meet trial criteria</li>
<li>Learn from past trials to improve future <a href="https://redbock.com/expertise/">resourcing strategies</a></li>
<li>Use conversational AI to pre‑screen candidates and assess eligibility</li>
</ul>
<p>These capabilities reduce administrative workload and help ensure that trials reach the right patients faster.</p>
<h3>Enhancing data quality and monitoring</h3>
<p>AI‑enabled monitoring tools support decentralized and hybrid trial models, allowing participants to take part remotely while maintaining data integrity. NLP and OCR systems can process unstructured clinical notes, and real‑time analytics help identify anomalies, improve accuracy, and support faster decision‑making. As these tools mature, clinical trials will become more adaptive and patient‑focused.</p>
<h2>AI and Personalized Healthcare</h2>
<p>Personalized medicine aims to tailor treatment to an individual&rsquo;s unique biology, lifestyle, and medical history. Advances in AI, ML, and predictive analytics are making this increasingly practical in everyday care.</p>
<h3>How AI supports personalized care</h3>
<p>AI can analyze a wide range of data sources, including:</p>
<ul>
<li>Genomic and proteomic data</li>
<li>Electronic health records</li>
<li>Wearable device data</li>
<li>Biosensor outputs</li>
<li>Real‑world evidence</li>
</ul>
<p>By spotting patterns and predicting disease risk, AI helps clinicians diagnose conditions earlier and choose more effective treatments. AI‑enabled personalization is becoming central to improving outcomes and reducing unnecessary interventions.</p>
<p>At present, these technologies already support healthcare professionals in understanding what a patient may be experiencing based on their genetics, symptoms, and broader health profile. More accurate diagnosis leads to more informed decisions about treatment, and, increasingly, prevention.</p>
<h3>Wearables and biosensors</h3>
<p>Digital health tools such as continuous glucose monitors and smartwatches generate a constant stream of real‑time data. AI can interpret this information to detect anomalies, track treatment response, and support early intervention. This improves patient outcomes and can reduce reliance on more expensive diagnostic procedures.</p>
<h2>AI in Diagnostics and Imaging</h2>
<p>Diagnostics is one of the fastest‑moving areas of AI in life sciences. Deep learning models can analyze medical images with impressive accuracy, supporting clinicians in detecting diseases earlier and more reliably.</p>
<p>AI is being used in:</p>
<ul>
<li>Oncology &ndash; tumor detection, segmentation, and classification</li>
<li>Cardiology &ndash; ECG interpretation and imaging analysis</li>
<li>Neurology &ndash; early identification of neurodegenerative conditions</li>
<li>Rare disease detection &ndash; pattern recognition across multimodal datasets</li>
</ul>
<p>Many AI‑enabled diagnostic tools have received regulatory clearance, and newer multimodal models that combine imaging data with clinical notes and laboratory results are giving clinicians a clearer, more reliable picture of a patient&rsquo;s condition. These systems are increasingly integrated into routine practice, helping ensure that important findings are recognized and acted on promptly.</p>
<h2>AI for Operational Efficiency Across Life Sciences</h2>
<p>Beyond R&amp;D and clinical work, AI is restructuring the operational backbone of life science organizations. GenAI and Agentic AI are beginning to automate complex, multi‑step workflows across manufacturing, supply chain, regulatory, and commercial functions.</p>
<h3>Examples of AI‑driven efficiency gains</h3>
<p>AI is now used to:</p>
<ul>
<li>Automate quality control in manufacturing</li>
<li>Predict equipment maintenance needs</li>
<li>Optimize supply chains</li>
<li>Forecast commercial demand</li>
<li>Automate regulatory document generation</li>
<li>Enhance pharmacovigilance and safety monitoring</li>
</ul>
<p>McKinsey estimates that generative AI could automate activities <a href="https://www.mckinsey.com/industries/life-sciences/our-insights/gen-ai-a-game-changer-for-biopharma-operations">representing up to 40% of working hours</a> across the economy, with biopharma among the sectors most exposed to these gains. As Agentic AI matures, organizations will be able to orchestrate end‑to‑end processes, from manufacturing planning to regulatory submissions with far greater speed and reliability.</p>
<h2>How Redbock Supports AI‑Driven Transformation in Life Sciences</h2>
<p>Redbock supports life science organizations as they adopt and embed AI by providing the specialized expertise needed to make these technologies work in real‑world settings. Our consultants support teams across R&amp;D, clinical, and operational workflows while building the capabilities required to use these tools effectively. We also guide organizations through digital transformation and change management efforts, ensuring new approaches fit within existing processes and meet regulatory expectations.</p>
<p>From drug discovery to modernizing clinical operations to exploring emerging GenAI applications, Redbock offers the experience and resourcing needed to move forward with clarity and confidence - <a href="https://redbock.com/contact/">get in touch with us today</a>.</p>
<hr>
<h2>FAQ: AI in Life Sciences</h2>
<h3>Which AI‑related skills are most in demand in life sciences?</h3>
<p>Roles involving data science, machine learning, bioinformatics, clinical data engineering, AI validation, and digital health expertise are increasingly essential as organizations adopt AI‑driven workflows.</p>
<h3>How does AI change the consulting needs of drug development and clinical teams?</h3>
<p>AI introduces new capabilities, such as predictive modelling, automated data processing, and digital trial management, which require hybrid skill sets combining scientific knowledge with data and technology expertise.</p>
<h3>What challenges do life science organizations face when implementing AI?</h3>
<p>Common challenges include data quality, regulatory compliance, change management, and integrating AI into legacy systems. Redbock helps organizations overcome these barriers through targeted consulting and specialized resourcing.</p>
<h3>How can Redbock help us scale AI initiatives responsibly?&nbsp;</h3>
<p>Redbock supports organizations with governance frameworks, validation expertise, and access to specialized consultants to ensure AI is deployed safely, ethically, and in alignment with regulatory expectations.</p>

Expertise

Biometrics

Clinical

Engineering

Program & Project Management

Quality

Regulatory & Compliance

Market leading insights in resourcing solutions

Life Sciences M&A Trends in 2026

How Is AI Pushing The Life Science Industry Forward?